Executive Summary
A single massive $20.65B DOE contract awarded to Lockheed Martin Services underscores long-term revenue stability for Y-12 plant management through Feb 2027, signaling bullish commitment to GOCO facilities operations amid full competition. No outlays despite 2026 period highlight execution risks tied to DOE budgeting. Investors should prioritize Lockheed Martin for defense/energy services exposure with potential follow-on beyond 2027.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior DOE Energy Grants digest from February 27, 2026.
Investment Signals (1)
- $20.65B Y-12 M&O Contract Extends to 2027 (HIGH)▲
Cost-plus award fee structure with full obligation provides 43-year revenue visibility for Lockheed Martin in Oak Ridge facilities operations.
Risk Flags (2)
- Execution [HIGH RISK]▼
$0 outlayed under long-term contract despite 2026 period may signal delays or funding holds.
- Regulatory [MEDIUM RISK]▼
Heavy reliance on annual DOE budgets for cost-plus reimbursements post-2027.
Opportunities (1)
- ◆
Fully funded structure (minimal base/options gap) positions Lockheed for seamless execution and follow-on Y-12 work.
Sector Themes (1)
- ◆
Full/open competition yields massive long-term awards like $20.65B Y-12 deal, emphasizing continuity in DOE R&D facilities.
Watch List (2)
- 👁
{"entity"=>"Lockheed Martin Corp", "reason"=>"Dominates single-record stream with $20.65B obligation; tracks DOE funding for revenue realization.", "trigger"=>"Outlays >$100M or 2027 extension announcements"}
- 👁
{"entity"=>"DOE Y-12 Program", "reason"=>"Concentration risk in one facility's M&O; no outlays signal broader DOE grant delays.", "trigger"=>"Budget shifts or competitor bids"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: DOE Energy Grants
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals